• Data
  • Studio
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Governance
    • Events
    • Newsroom
    • Careers
Get started
Sign in
Real-time monitoring of prescription trends and demographics of two SGLT2i drugs

Real-time monitoring of prescription trends and demographics of two SGLT2i drugs

by Truveta Research | Jul 10, 2023 | Research, Research Insights

We explored the demographic characteristics of patients with type 2 diabetes mellitus, heart failure, and chronic kidney disease who received a prescription for empagliflozin (Jardiance) and/or dapagliflozin (Farxiga), two commonly used SGLT2i drugs. We saw...

Share this


Recent posts

  • First real-world comparative effectiveness study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss
  • Beyond claims data: Truveta showcases potential of EHR data at ISPOR EU 2023
  • Reflections from the inaugural Truveta Symposium

Follow Truveta


Stay up-to-date

Ready to join us on our mission of Saving Lives with Data?

Get started
  • Follow
  • Follow

Truveta Data

Truveta Studio

Research

Resources

Blog

Leadership

Governance

Newsroom

Careers

Contact us

Privacy Notice

© Truveta 2023

Interested in learning more?

Reach out and we’ll schedule a demo.